180 related articles for article (PubMed ID: 31502695)
21. Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.
Tan-Koi WC; Lim ES; Teo YY
Pharmacogenomics J; 2017 Mar; 17(2):121-127. PubMed ID: 26902540
[TBL] [Abstract][Full Text] [Related]
22. Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny.
Corriol-Rohou S; Cheung SYA
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S112-S119. PubMed ID: 31502694
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
24. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
[TBL] [Abstract][Full Text] [Related]
25. International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States.
Song YK; Han N; Burckart GJ; Oh JM
Clin Pharmacol Ther; 2020 Mar; 107(3):530-540. PubMed ID: 31544241
[TBL] [Abstract][Full Text] [Related]
26. Implementation of pharmacogenomics in product information.
Skvrce NM; Krivokapić S; Božina N
Pharmacogenomics; 2020 May; 21(7):443-448. PubMed ID: 32336208
[No Abstract] [Full Text] [Related]
27. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels.
Wang B; Canestaro WJ; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1938-44. PubMed ID: 25317785
[TBL] [Abstract][Full Text] [Related]
28. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
29. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.
Cacabelos R; Naidoo V; Corzo L; Cacabelos N; Carril JC
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948113
[TBL] [Abstract][Full Text] [Related]
30. Pediatric Drug Development: Outlook for Science-Based Innovation.
Green DJ; Zineh I; Burckart GJ
Clin Pharmacol Ther; 2018 Mar; 103(3):376-378. PubMed ID: 29384202
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenomics: history, barriers, and regulatory solutions.
Blankstein S
Food Drug Law J; 2014; 69(2):273-314, ii. PubMed ID: 25163212
[TBL] [Abstract][Full Text] [Related]
32. Improving pediatric dosing through pediatric initiatives: what we have learned.
Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
[TBL] [Abstract][Full Text] [Related]
33. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
Vivot A; Boutron I; Ravaud P; Porcher R
Genet Med; 2015 Sep; 17(9):733-8. PubMed ID: 25521333
[TBL] [Abstract][Full Text] [Related]
34. Ontogeny and drug metabolism in newborns.
Dotta A; Chukhlantseva N
J Matern Fetal Neonatal Med; 2012 Oct; 25 Suppl 4():83-4. PubMed ID: 22958028
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020).
Kim JA; Ceccarelli R; Lu CY
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33806453
[TBL] [Abstract][Full Text] [Related]
36. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science.
Leeder JS; Kearns GL; Spielberg SP; van den Anker J
J Clin Pharmacol; 2010 Dec; 50(12):1377-87. PubMed ID: 20150527
[TBL] [Abstract][Full Text] [Related]
37. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
[TBL] [Abstract][Full Text] [Related]
38. Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan.
Hikino K; Fukunaga K; Mushiroda T
Drug Metab Pharmacokinet; 2018 Dec; 33(6):243-249. PubMed ID: 30360950
[TBL] [Abstract][Full Text] [Related]
39. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
Phillips KA; Van Bebber SL
Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395
[TBL] [Abstract][Full Text] [Related]
40. Conference report: pharmacogenomics in special populations at WCP2018.
Suarez-Kurtz G; Aklillu E; Saito Y; Somogyi AA
Br J Clin Pharmacol; 2019 Mar; 85(3):467-475. PubMed ID: 30537134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
